Last reviewed · How we verify

La Fundacion Favaloro para la Investigacion y la Docencia Medica — Portfolio Competitive Intelligence Brief

La Fundacion Favaloro para la Investigacion y la Docencia Medica pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Flu Vaccine Flu Vaccine marketed Prophylactic vaccine Influenza A and B viral hemagglutinin and neuraminidase surface antigens Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Fondazione IRCCS Policlinico San Matteo di Pavia · 1 shared drug class
  2. GlaxoSmithKline · 1 shared drug class
  3. Murdoch Childrens Research Institute · 1 shared drug class
  4. National Cancer Institute (NCI) · 1 shared drug class
  5. Peking Union Medical College Hospital · 1 shared drug class
  6. Shanghai Zerun Biotechnology Co.,Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for La Fundacion Favaloro para la Investigacion y la Docencia Medica:

Cite this brief

Drug Landscape (2026). La Fundacion Favaloro para la Investigacion y la Docencia Medica — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/la-fundacion-favaloro-para-la-investigacion-y-la-docencia-medica. Accessed 2026-05-17.

Related